10-Q: TherapeuticsMD Reports Q1 2026 Financials, Focus on Royalty Revenue

TherapeuticsMD, Inc. transitioned to a pharmaceutical royalty company, reporting increased license revenue and net income for the first quarter of 2026, while navigating ongoing legal disputes.

Summary

• TherapeuticsMD, Inc. reported license revenue of $724,000 for the first quarter of 2026, an increase from $393,000 in the same period of 2025.
• The company achieved a net income of $95,000 for Q1 2026, a significant improvement from a net loss of $653,000 in Q1 2025.
• General and administrative expenses decreased by 9.3% to $1,353,000 in Q1 2026 compared to $1,491,000 in Q1 2025, primarily due to lower professional fees and share-based compensation.
• The company continues to be involved in significant legal proceedings with Mayne Pharma concerning net working capital adjustments and patent infringement litigation related to IMVEXXY.
• Substantial doubt exists regarding the company's ability to continue as a going concern due to potential liquidity needs and uncertainties surrounding the Mayne Pharma litigation and future financing.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly positive report, with clear improvements in revenue and profitability, but significant ongoing risks related to litigation and going concern status.

Positives

• License revenue increased by 85% to $724,000 in Q1 2026 compared to $393,000 in Q1 2025.
• The company reported a net income of $95,000 in Q1 2026, a substantial turnaround from a net loss of $653,000 in Q1 2025.
• Operating expenses decreased by 13.6% to $1,447,000 in Q1 2026 from $1,674,000 in Q1 2025, driven by lower G&A expenses and the absence of patent write-offs.
• Other income, net, increased to $826,000 in Q1 2026 from $613,000 in Q1 2025, boosted by higher sublease income and ANNOVERA royalty sales.

Negatives

• The company's ability to continue as a going concern is subject to substantial doubt due to potential liquidity requirements and uncertainties related to ongoing litigation and future financing.
• Significant legal disputes with Mayne Pharma are ongoing, involving claims for breach of contract, fraudulent inducement, and indemnification demands, creating financial uncertainty.
• The company has a substantial accumulated deficit of $952,296,000 as of March 31, 2026.
• The company may need to raise additional capital, which could dilute existing stockholders' ownership interests and potentially include unfavorable terms.

Risks

• The outcome of the Mayne Lawsuits and Mayne Countersuit is uncertain and could materially impact financial condition.
• Mayne Pharma's potential sale to Cosette Pharmaceuticals, Inc. could affect future royalty streams.
• If Mayne Pharma's sales of licensed products grow more slowly than expected or decline, the company's cash reserves may be insufficient.
• The company faces risks related to future financings and potential supply chain issues with third-party contract manufacturers.
• Patent infringement litigation concerning IMVEXXY with Teva and Sun Pharma poses a risk to future revenue streams.
• The company's ability to continue as a going concern is uncertain, raising doubts about its long-term viability without additional financing.

Future Outlook

The company's primary revenue source is royalties from licensed products. It may need to raise additional capital through equity or debt financing to fund operations. The company is exploring strategic alternatives, but there is no assurance of a transaction or its outcome.

Management Comments

• Management believes its estimated allowances for payer rebates and wholesale distributor fees are reasonable, despite differences with Mayne Pharma's calculations.
• Management continues to monitor unresolved net working capital items with Mayne Pharma, noting that changes could be material.
• Management has evaluated the effectiveness of disclosure controls and procedures and concluded they are effective.
• Management does not expect internal controls to prevent all errors and fraud, acknowledging inherent limitations.

Industry Context

StockSavvy.ai notes that TherapeuticsMD's transition to a royalty company reflects a strategic shift common in the pharmaceutical sector, focusing on leveraging intellectual property rather than direct commercialization. The ongoing litigation with Mayne Pharma highlights the complexities and potential disputes that can arise from large licensing and asset sale agreements in this industry.

Comparison to Industry Standards

• The royalty rates of 8.0% on the first $80 million and 7.5% on sales above $80 million are within typical ranges for pharmaceutical licensing agreements, though specific product lifecycles and market exclusivity can influence these rates.
• The minimum annual royalty of $3.0 million, adjusted for inflation, provides a baseline revenue stream, which is a common feature in such agreements to ensure a minimum return for the licensor.
• The company's focus on women's health products (IMVEXXY, BIJUVA, ANNOVERA, prenatal vitamins) aligns with a specialized segment of the pharmaceutical market, though competition from generic versions and other therapeutic alternatives is a constant industry factor.

Legal Proceedings

• Mayne Lawsuit: Filed by TherapeuticsMD against Mayne Pharma for breach of contract, fraudulent inducement, etc., related to net working capital allowances. A magistrate judge recommended granting some claims and denying others, and staying the lawsuit pending dispute resolution.
• Mayne Countersuit: Filed by Mayne Pharma against TherapeuticsMD for breach of contract and fraudulent inducement. A magistrate judge recommended dismissing the fraudulent inducement claim but denying dismissal of other claims.
• IMVEXXY Patent Litigation (Teva): TherapeuticsMD filed a patent infringement complaint against Teva Pharmaceuticals USA, Inc. for its generic version of IMVEXXY. Proceedings were stayed and then lifted; litigation is ongoing.
• IMVEXXY Patent Litigation (Sun Pharma): TherapeuticsMD and Mayne Pharma filed a patent infringement complaint against Sun Pharma Inc. for its generic version of IMVEXXY. Litigation is ongoing.

Related Party Transactions

• Subscription Agreement with Rubric Capital Management LP: Allows for the sale of up to 5,000,000 shares of common stock. Drawdowns occurred in June and November 2023.
• Director Justin Roberts is a Partner of Rubric Capital Management LP, which has entered into subscription agreements with the company.

Stakeholder Impact

• Shareholders: Potential dilution from future capital raises; ongoing uncertainty due to litigation and going concern status.
• Creditors: Potential impact on ability to meet obligations if financing is not secured or litigation outcomes are unfavorable.
• Partners (e.g., Mayne Pharma, Knight, Theramex): Continued reliance on these partners for royalty generation; ongoing disputes with Mayne Pharma create uncertainty.

Next Steps

• Continue to monitor and manage ongoing legal proceedings with Mayne Pharma.
• Evaluate and pursue potential strategic alternatives, which may include acquisition, merger, or sale of assets.
• Seek additional capital through equity or debt financing if necessary to fund operations.
• Continue to receive royalties from licensed products under existing agreements.

Key Dates

Recommendation

The company shows signs of financial recovery with increased revenue and a return to profitability. However, significant ongoing litigation with Mayne Pharma and substantial doubt about its ability to continue as a going concern introduce considerable risk. While the royalty model provides a path forward, the uncertainties warrant a cautious 'hold' recommendation until these risks are resolved or mitigated.

Keywords

TherapeuticsMD, 10-Q, Quarterly Report, Royalty Revenue, License Agreement, Mayne Pharma, IMVEXXY, BIJUVA, ANNOVERA, Financial Statements, Going Concern, Legal Proceedings, Patent Litigation